Institute of Biochemistry, Carleton University, 1125 Colonel By Drive, Ottawa, ON K1N 5B6, Canada.
Biomolecules. 2024 Sep 3;14(9):1112. doi: 10.3390/biom14091112.
The dual methyltransferase methyltransferase-like protein 13, also referred to as METTL13, or formerly known as FEAT (faintly expressed in healthy tissues, aberrantly overexpressed in tumors), has garnered attention as a significant enzyme in various cancer types, as evidenced by prior literature reviews. Recent studies have shed light on new potential roles for METTL13, hinting at its promise as a therapeutic target. This review aims to delve into the multifaceted biology of METTL13, elucidating its proposed mechanisms of action, regulatory pathways, and its implications in disease states, as supported by the current body of literature. Furthermore, the review will highlight emerging trends and gaps in our understanding of METTL13, paving the way for future research efforts. By contextualizing METTL13 within the broader landscape of cancer biology and therapeutics, this study serves as an introductory guide to METTL13, aiming to provide readers with a thorough understanding of its role in disease phenotypes.
双甲基转移酶甲基转移酶样蛋白 13，也称为 METTL13，或以前称为 FEAT（在健康组织中微弱表达，在肿瘤中异常过表达），作为各种癌症类型中的重要酶，已经引起了关注，这一点可以从之前的文献综述中得到证明。最近的研究揭示了 METTL13 的新的潜在作用，暗示其有望成为治疗靶点。本综述旨在深入探讨 METTL13 的多方面生物学特性，阐明其作用机制、调节途径及其在疾病状态下的意义，这一观点得到了现有文献的支持。此外，该综述还将突出我们对 METTL13 理解中的新兴趋势和差距，为未来的研究工作铺平道路。通过将 METTL13 置于癌症生物学和治疗学的更广泛背景下，本研究旨在为 METTL13 提供一个介绍性指南，旨在为读者提供对其在疾病表型中的作用的全面理解。
